July 2024 – Page 237 – Get News Story

Diner 24 NYC Launches 24-Hour Delivery Service Across Manhattan

“The image showcases Diner 24 NYC’s retro-style exterior sign and a glimpse of its cozy interior, highlighting the classic American diner ambiance.”

Diner 24 NYC, Manhattan’s premier 24-hour diner, announces the launch of its 24-hour delivery service, available through Grubhub, DoorDash, and Uber Eats. Located at 283 3rd Ave, NYC, Diner 24 NYC combines classic diner charm with modern culinary excellence. Offering an extensive menu including all-day breakfast, gourmet burgers, and vegetarian options, Diner 24 NYC ensures delicious meals are just a click away, anytime, anywhere in Manhattan.

Diner 24 NYC, Manhattan’s premier 24-hour diner, is thrilled to announce the launch of its 24-hour diner nyc delivery service, making delicious, freshly prepared meals available around the clock to residents and visitors throughout Manhattan. This new service brings the convenience and comfort of Diner 24’’s renowned menu directly to your doorstep, no matter the time of day or night.

Bringing Back the Iconic NYC Diner Culture

Diner 24 NYC, located in the heart of manhattan, is the brainchild of co-founders Stratis Morfogen and Philippe Olivier Bondon, who are passionate about reviving the classic New York City diner experience. Inspired by the iconic 24-hour diners that have been a staple of NYC culture for over a century, Diner 24 NYC aims to combine the nostalgic charm of traditional diners with modern culinary excellence and cutting-edge technology.

“During the pandemic, we witnessed the unfortunate closure of many beloved 24-hour diners in the city,” said Stratis Morfogen. “We saw an opportunity to bring back this quintessential New York experience, and with Diner 24 NYC, we’re not only preserving a piece of the city’s history but also elevating it with high-quality ingredients and innovative dishes.”

A Diverse Menu for All Cravings

Diner 24 NYC offers an extensive menu that caters to a wide range of tastes and preferences. From classic diner staples like all-day breakfast, juicy burgers, and Greek salads to modern twists on traditional dishes, there is something for everyone at any hour. The menu features:

Breakfast Anytime: Enjoy fluffy pancakes, crispy waffles, and hearty omelets whenever the craving strikes.
12oz Smash Burgers: Signature burgers made with premium ingredients, including the famous Bacon Cheeseburger and Turkey Burger.
Greek Favorites: Fresh salads and spreads, such as the Greek Salad and Charcoal Eggplant.
Handcrafted Sandwiches: Unique creations like the Surf & Turf Sandwich and the Grilled Cheese Sandwich.
Vegetarian Options: Delicious choices including Carrot Hummus and Crispy Zucchini Kebobs.

The diner’s best-seller, the Chicken Parm Sandwich, showcases Morfogen’s innovative approach to traditional recipes. “I love to deconstruct or disrupt everything I do,” he explains. “Our Chicken Parm Sandwich features a great piece of Bell and Evans chicken breast with vodka sauce, topped with a whole bowl of burrata and cured peppers.”

Easy Ordering, Fast Delivery

Diner 24 NYC is not just about great food; it’s also about enhancing the customer experience through technology. Morfogen, a pioneer in integrating technology with dining, has ensured that Diner 24 NYC stays ahead of the curve. “People search for 24 hour diner nyc, breakfast, and burgers from 10 p.m. to 6 a.m. We get about a million impressions a month just within 20 blocks of the diner in Gramercy,” says Morfogen.

With this tech-savvy approach, ordering from Diner 24 is seamless and convenient. Customers can easily place their orders online through delivery platforms like Grubhub, DoorDash, and Uber Eats, ensuring that their favorite meals are just a few clicks away.

24-Hour Delivery Across Manhattan

The launch of the 24-hour delivery service is set to revolutionize late-night dining in Manhattan. Whether you’re in Midtown, Times Square, Hell’s Kitchen, Chelsea, Gramercy, East Village, Lower East Side, Kips Bay, NoMad, Hudson Yards, Tribeca, Chinatown, Hunters Point, Long Island City, Murray Hill, or the Flatiron District, Diner 24’s delivery service ensures that you can enjoy gourmet meals at any hour.

“We are excited to bring our 24-hour delivery service to Manhattan,” says Philippe Olivier Bondon. “No matter where you are or what time it is, Diner 24 NYC is here to satisfy your cravings with delicious, freshly prepared meals.”

Unique Offerings and Community Focus

Diner 24 NYC prides itself on being more than just a place to eat; it’s a community hub. The diner’s cozy interior features nostalgic elements like old-fashioned coffee shop napkin holders and jukeboxes, blending seamlessly with modern amenities such as Bluetooth connectivity for personal music at your booth. This hybrid approach ensures that while diners experience a touch of the past, they also enjoy the conveniences of today.

In addition to the extensive menu, Diner 24 NYC offers catering services for events of all sizes. Whether it’s a corporate event, family gathering, or casual get-together, Diner 24’s catering menu includes a variety of options to suit any occasion. Customers can choose from trays of appetizers, salads, sandwiches, and more, ensuring that their events are both delicious and memorable.

A Visionary Team

The success of Diner 24 NYC can be attributed to the visionary leadership of Morfogen and Bondon. Morfogen, a third-generation Greek-American restaurateur, has a long history of innovative concepts in the hospitality industry. He brought the Fulton Fish Market online in 1997, a groundbreaking move at the time, and continues to integrate technology with dining experiences.

Bondon, with his extensive background in both the New York and international restaurant scenes, adds a global perspective to Diner 24 NYC. His entrepreneurial journey includes successful ventures in France and Portugal before joining forces with Morfogen to bring Diner 24 NYC to life.

Customer Testimonials

Diner 24 NYC has quickly become a favorite among locals and visitors alike. With 4.3 star rating on Google and Yelp, customers rave about the impeccable service, tasty food, and the welcoming atmosphere. “The service is impeccable, the food tasty, and the owner was so personable!” reads one review. Another customer highlights the diner’s specialties: “Great service, the French dip and milkshake were very flavorful.”

For more information, visit diner24nyc.com or follow Diner 24 on Instagram, Twitter, and Facebook.

Media Contact
Company Name: Diner 24 NYC
Contact Person: Marketing Manager
Email: Send Email
Phone: (646) 852-6921
Address:283 3rd Ave
City: New York
State: New York 10010
Country: United States
Website: diner24nyc.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diner 24 NYC Launches 24-Hour Delivery Service Across Manhattan

Lupus Nephritis Pipeline Insights 2024: Therapies, Clinical Trials by DelveInsight | Roche, Equillium, BeiGene, Janssen R&D, Horizon Therapeutics, Novartis, Roche, AstraZeneca

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Lupus Nephritis pipeline constitutes 20+ key companies continuously working towards developing 25+ Lupus Nephritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Lupus Nephritis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lupus Nephritis Market.

The Lupus Nephritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Lupus Nephritis Pipeline Report:

Companies across the globe are diligently working toward developing novel Lupus Nephritis treatment therapies with a considerable amount of success over the years.
Lupus Nephritis companies working in the treatment market are Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others, are developing therapies for the Lupus Nephritis treatment

Emerging Lupus Nephritis therapies in the different phases of clinical trials are- IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others are expected to have a significant impact on the Lupus Nephritis market in the coming years.
In February 2024, ImmPACT Bio has received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) for its Phase Ib/II clinical trial of IMPT-514, aimed at treating refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE). IMPT-514 is a CD19/CD20-targeting bispecific chimeric antigen receptor (CAR) T-cell therapy designed to deplete autoreactive immune cells. This open-label dose escalation trial will enroll participants with active, refractory SLE who have previously undergone at least two standard-of-care therapies.
In September 2023, Kyverna Therapeutics, a clinical-stage cell therapy company focused on developing treatments for serious autoimmune diseases, announced that KYV-101 was generally well tolerated with no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) reported during the standard 28-day post-infusion observation period for the first U.S. patient enrolled in its Phase 1 clinical trial for relapsed or refractory lupus nephritis (LN). The KYV-101 infusion took place earlier in July at the University of Colorado Anschutz Medical Campus.
In July 2023, Kyverna Therapeutics (“Kyverna”), a cell therapy company with the goal of creating a new class of treatments for severe autoimmune diseases, announced today that the Paul-Ehrlich-Institut (PEI) in Germany has approved its first Clinical Trial Application (CTA) for KYV101, a cutting-edge therapy for the treatment of lupus nephritis (LN). In order to treat autoimmune disorders caused by B cells, such as LN, KYV-101 is a unique, totally human anti-CD19 CAR T-cell therapy. It provides a ground-breaking strategy for battling autoimmune diseases by utilising the body’s immune system

Lupus Nephritis Overview

Lupus nephritis is a serious complication of systemic lupus erythematosus (SLE), an autoimmune disease where the body’s immune system mistakenly attacks its own tissues. In lupus nephritis, the immune system targets the kidneys, leading to inflammation and potentially causing kidney damage.

Get a Free Sample PDF Report to know more about Lupus Nephritis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight

Emerging Lupus Nephritis Drugs Under Different Phases of Clinical Development Include:

Secukinumab: Novartis
Obinutuzumab: Roche
GAZYVA: Roche
Saphnelo (Anifrolumab): AstraZeneca
Iscalimab: Novartis
IBL-101: Inflection Biosciences
RG 6107: Roche
Itolizumab: Equillium
Zanubrutinib: BeiGene
Guselkumab: Janssen Research & Development
Daxdilimab: Horizon Therapeutics
Cosentyx: Novartis
Ravulizumab: Alexion Pharmaceuticals
Anifrolumab: AstraZeneca

Lupus Nephritis Route of Administration

Lupus Nephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Lupus Nephritis Molecule Type

Lupus Nephritis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Lupus Nephritis Pipeline Therapeutics Assessment

Lupus Nephritis Assessment by Product Type
Lupus Nephritis By Stage and Product Type
Lupus Nephritis Assessment by Route of Administration
Lupus Nephritis By Stage and Route of Administration
Lupus Nephritis Assessment by Molecule Type
Lupus Nephritis by Stage and Molecule Type

DelveInsight’s Lupus Nephritis Report covers around 25+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Lupus Nephritis product details are provided in the report. Download the Lupus Nephritis pipeline report to learn more about the emerging Lupus Nephritis therapies

Some of the key companies in the Lupus Nephritis Therapeutics Market include:

Key companies developing therapies for Lupus Nephritis are – Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.

Lupus Nephritis Pipeline Analysis:

The Lupus Nephritis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Lupus Nephritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lupus Nephritis Treatment.
Lupus Nephritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Lupus Nephritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lupus Nephritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Lupus Nephritis drugs and therapies

Lupus Nephritis Pipeline Market Drivers

Increasing Prevalence of Lupus Nephritis, increase in research and developmental activities are some of the important factors that are fueling the Lupus Nephritis Market.

Lupus Nephritis Pipeline Market Barriers

However, high-cost associated with the disease, lack of awareness among the patients about the disease and other factors are creating obstacles in the Lupus Nephritis Market growth.

Scope of Lupus Nephritis Pipeline Drug Insight

Coverage: Global
Key Lupus Nephritis Companies: Inflection Biosciences, Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca, Novartis, Alexion Pharmaceuticals, AstraZeneca, Equillium, and others
Key Lupus Nephritis Therapies: IBL-101, RG 6107, Itolizumab, Zanubrutinib, Guselkumab, Daxdilimab, Secukinumab, Obinutuzumab, GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Ravulizumab, Anifrolumab, Itolizumab, and others
Lupus Nephritis Therapeutic Assessment: Lupus Nephritis current marketed and Lupus Nephritis emerging therapies
Lupus Nephritis Market Dynamics: Lupus Nephritis market drivers and Lupus Nephritis market barriers

Request for Sample PDF Report for Lupus Nephritis Pipeline Assessment and clinical trials

Table of Contents

1. Lupus Nephritis Report Introduction

2. Lupus Nephritis Executive Summary

3. Lupus Nephritis Overview

4. Lupus Nephritis- Analytical Perspective In-depth Commercial Assessment

5. Lupus Nephritis Pipeline Therapeutics

6. Lupus Nephritis Late Stage Products (Phase II/III)

7. Lupus Nephritis Mid Stage Products (Phase II)

8. Lupus Nephritis Early Stage Products (Phase I)

9. Lupus Nephritis Preclinical Stage Products

10. Lupus Nephritis Therapeutics Assessment

11. Lupus Nephritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Lupus Nephritis Key Companies

14. Lupus Nephritis Key Products

15. Lupus Nephritis Unmet Needs

16 . Lupus Nephritis Market Drivers and Barriers

17. Lupus Nephritis Future Perspectives and Conclusion

18. Lupus Nephritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lupus Nephritis Pipeline Insights 2024: Therapies, Clinical Trials by DelveInsight | Roche, Equillium, BeiGene, Janssen R&D, Horizon Therapeutics, Novartis, Roche, AstraZeneca

Food Packaging Market to Promise Magnificent 5.7% CAGR through 2031

“Skyquest Technology”

Food Packaging Market Size, Share, Growth Analysis, By Materials(Paper & board, Metal, Rigid plastic, Flexible plastic), By Types(Rigid, Semi-Rigid, Flexible), By Application(Bakery, Confectionery, Convenience foods, Dairy products), By Region – Industry Forecast 2024-2031

Food Packaging Market size was valued at USD 361.4 Billion in 2022 and is expected to grow from USD 382 Billion in 2023 to reach USD 595.2 Billion by 2031, at a CAGR of 5.7% during the forecast period (2024-2031).

The global Food Packaging Management market has always been adjusting to meet the ever-increasing consumer demand. Today, improved and appealing packaging along with solutions for sustainability is considerably impacting the decision-making power of consumers. People understand the importance of food safety and nutritious consumables, thereby impacting the market growth.

The growing population worldwide demands increased food production. Hence, the three key focus areas for food manufacturers include food safety, food availability, and sustainability. Only with the interaction of these essentials, the market could drive effective and efficient innovation to create safe and sustainable food items. Consumers today believe that the safety of food should be the priority of the manufacturers. And this undoubtedly needs to focus on reconsidering food production and adopting solutions that benefit all players in the chain, from the farmer to the end consumer. Food availability is yet another key factor, for which it is important to create a regulated and sustainable food value chain. For food sustainability, there must be ideal synchronization between the environmental regulation and legislature for food contact material, to avoid compromises.

Download a detailed overview:

https://www.skyquestt.com/sample-request/food-packaging-market

Increasing Adoption of Unique Packaging Materials to Support Sustainability in Market

The growing demand for sustainability is forcing manufacturers to adopt different eco-friendly packaging materials like recycled paper, biodegradable plastics, and plant-based packaging. Simple yet classy packaging design is trending among consumers since it focuses on the product inside. This is more prominently seen in the wellness and healthcare domain, where the products need to be clean and with the simplest wrapping. Interactive packaging trends include QR codes that allow consumers to know more about the product. The market is also experiencing smart packaging fixed with sensors and technologies that help consumers know more about nutritional details, storage advice, and freshness. Besides these, the transparency trend is gaining traction since it offers accurate and clear information about products and their ingredients. Consumers are growing health-conscious and buy products that are free from harmful additives and chemicals. Eco-friendly packaging is also driving the market since it uses sustainable materials and consumers are becoming aware of the negative impact on surroundings and purchase items that are packaged with sustainable processes.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/food-packaging-market

ITC claimed in 2023 that it finished sustainability of 60000 Mt plastic waste. This rate exceeded the quantities of plastic used in the previous year. The company augments the manufacturing of recyclable laminates containing less amount of plastic content.
In 2023, Dabur was presented with the title of ‘plastic waste positive business’. The company collected, processed, as well as recycled approximately 30000 Mt ofwaste of plastic in the year 2022-23. On the eve of World Environment Day, the company made this announcement.
Nestlé, in September 2023, announced that the company disclosed its actions and stepped towards making a waste-free world. The company made efforts to embrace sustainable packaging of its products. Nestlé company planned to minimize the use ofvirgin plastics by 1/3 by 2023end.
In June 2023, Hindustan Unilever Limited, declared to reduceusing virgin plastic for the environment. Nitin Paranjpe, the chairman, said that plastic is not very important for the company, but environment also needs proper care. Hence, he announced reduced use of virgin plastic, and the use ideal quantity of recycled plastic. This will make the packaging 100% reusable, compostable, and recyclable. The company plans to collect more plastic by the end of 2025.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/food-packaging-market

With this being the scenario, the Food Packaging Market is projected to deal with different challenges and focus on opportunities, environmental safety, and commitment toward a better future. The journey for sustainable packaging options is not just the industry authority, but also collective accountability for a healthy and sustainable food network.

Related Reports:

Drone (UAV) Market

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/food-packaging-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Packaging Market to Promise Magnificent 5.7% CAGR through 2031

CBASOX Exchange Achieves World-Leading Transaction Speed of 1.5 Million Orders per Second

CBASOX Exchange, renowned for its innovation in the cryptocurrency trading sector, recently announced the successful upgrade of its AI algorithm trading engine, achieving an astounding speed of processing 1.5 million transactions per second. This technological breakthrough significantly enhances trading efficiency, elevating the service quality of CBASOX to unprecedented heights.

In the cryptocurrency market, transaction speed is a critical metric for evaluating the performance of an exchange. With this upgrade, CBASOX effectively alleviates trading pressure during market peaks, ensuring smooth and stable transactions, thereby greatly improving user experience. This achievement underscores the ongoing dedication of CBASOX to technological innovation and service optimization.

This breakthrough is attributed to the formidable capabilities of the AI algorithm trading engine of CBASOX. This engine employs cutting-edge artificial intelligence technology and algorithms, enabling real-time market data analysis and trend prediction, thereby optimizing trading strategies and enhancing transaction speed. The successful implementation of the AI algorithm trading engine not only showcases the leading position of CBASOX in technological innovation but also sets a new technical standard for the entire cryptocurrency trading industry.

In addition to the remarkable increase in transaction speed, CBASOX Exchange has made significant contributions to security and user-friendliness. By adopting a distributed architecture and multi-layer security measures, the platform ensures stability and the safety of user assets. Simultaneously, CBASOX continuously refines the user interface and trading processes, allowing users to trade in a more intuitive and convenient environment.

Toby, a member of the CBASOX team, stated, “We are committed to technological innovation and enhancing user experience. The successful upgrade of our AI algorithm trading engine has not only positioned us as a global leader in transaction speed but also provided robust support for our relentless pursuit of security and user-friendliness.” He emphasized that CBASOX will continue to explore and apply cutting-edge technologies, providing a safer and more convenient trading environment for users worldwide.

The rapid development and continuous innovation of CBASOX Exchange are not only earning widespread recognition from global users but also providing crucial technical support and direction for the growth of the cryptocurrency exchange industry. As the cryptocurrency market continues to mature and expand, CBASOX is poised to persist in its commitment to technological innovation and service optimization, delivering safer, more efficient, and convenient trading services to users, and driving the healthy development of the global cryptocurrency market.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: CBASOX DIGITAL TRADE LIMITED
Contact Person: Kim Min-su
Email: Send Email
Country: United States
Website: https://www.cbasox.org

Exploring Themes of Transformation & Growth – Boorook Releases Evocative New Single “Dissolution”

Indigenous icon Boorook unveils “Dissolution,” a powerful single that delves into personal growth and emotional metamorphosis, enriching his discography

A stunning, unprecedented release, Boorook’s “Dissolution” skillfully combines contemporary modern beats with emotionally charged lyrics, inviting listeners to contemplate their personal journeys of breaking down barriers and embracing new beginnings.

The scintillating and sublime track, produced by the innovative Ryini Beats and featuring a heartfelt contribution from Boorook’s 9-year-old son, resonates with authenticity and depth. The song “Dissolution” not only captivates with its music but also acts as a catalyst for introspection and societal transformation. It delves into mental health issues, exploring ways to find positive coping mechanisms amidst challenges.

Raised in a family deeply involved in the Indigenous rights movement, eclectic artist and soundmaker Boorook’s artistic expression is heavily influenced by the teachings of his Elders and the rich stories of his community. The artist’s characteristic music stands apart from most contemporary artistic productions as it beautifully addresses critical themes such as equality, social justice, environmental awareness, and the celebration of Blak excellence. Through his songs, Boorook aims to educate and bridge cultural gaps, fostering a deeper understanding and respect for Indigenous cultures and illuminating the truth for all.

Boorook’s influence extends beyond mere musical expression. As the talented artist prepares for the release of more singles and an upcoming EP, he remains committed to pushing creative boundaries and exploring new musical territories. His upcoming plans include embarking on a tour to connect with fans worldwide and collaborating with other artists to expand his musical impact.

In an era calling for transformative change, Boorook’s voice resonates more powerfully than ever, guiding listeners through a journey of introspection and cultural appreciation. His continued dedication to his craft and his community ensures that his music will leave a lasting impact, inspiring future generations to understand more deeply and act more thoughtfully. As “Dissolution” sails into the hearts of listeners, it marks another milestone in Boorook’s remarkable career, promising to be a memorable addition to the vibrant tapestry of modern music.

Listeners are encouraged to experience “Dissolution” and immerse themselves in its introspective narrative. The single is available on all major streaming platforms, where fans can also follow Boorook to stay updated with his latest releases and tour information. Boorook’s music not only offers an auditory experience but also an invitation to engage with issues that matter, promoting cultural awareness and mutual respect through the power of music!

ABOUT

Boorook, the esteemed and iconic Indigenous cultural artist from the Keeray Wooroong nation of Warrnambool, has been a pivotal figure in the music scene since 2017. With his unique blend of conscious music, Boorook articulates the experiences, struggles, and victories of First Nations people. The artist’s latest single, “Dissolution,” released in May 2024, embarks on a profound exploration of personal transformation and the journey of self-discovery. Through his enigmatic, moving, and immersive content, the artist continues a beautiful trajectory in the world of music.

LINKS

Facebook: https://www.facebook.com/gunditj/

Instagram: https://www.instagram.com/boorook90/

Twitter: https://x.com/Boorook3

YouTube: https://www.youtube.com/channel/UCvGadioECwK8j2qPj46ZqEw

Spotify: https://open.spotify.com/artist/5EUMJiwAoKYtXZRHVfgdUA?si=BOcqm378Q0GrLNL5_knj5Q

SoundCloud: https://soundcloud.com/boorook-gundidj

LinkedIn: https://au.linkedin.com/in/brett-clarke-aka-boorook-kirrae-whurrung-artist-97249938

Media Contact
Company Name: Boorook
Email: Send Email
Phone: 800-983-1362
City: Warrnambool
State: Victoria
Country: Australia
Website: https://www.facebook.com/gunditj/

Talented Artist Tony Levitas Triumphs with New Album “Shadows” Following Near-Death Experience

After overcoming a life-threatening illness, Tony Levitas announces the release of his fifth album, “Shadows,” a deep dive into Southern Americana and Dream Pop

“Shadows” was born from a place of gratitude and introspection, following Tony’s near-death experience with Covid-19 in 2020. The album’s tracks weave through themes of light and dark, survival and rebirth, resonating with Levitas’s influences from Bob Dylan to Neil Young, while also drawing comparisons to Tom Petty and The Velvet Underground. Each song serves as a testament to his journey, blending elements of Americana with the ethereal qualities of Dream Pop to create a sound that is uniquely his.

Tony’s musical career is rich and varied, having been a significant figure in the band Arms Akimbo, which saw notable success including a video on MTV and performances alongside major acts like the Ramones and R.E.M. With “Shadows,” he continues to build on his legacy, offering a collection of songs that are not only personal but universal in their appeal.

In addition to his own performances, Tony is passionate about sharing his music more broadly. He is keen on providing songs for other artists as well as for film and TV, hoping to expand his influence and connect with even more listeners through different mediums. This album is more than just another milestone; it’s a declaration of his ongoing evolution as an artist and a survivor.

Fans and new listeners alike are encouraged to experience “Shadows,” available on all major streaming platforms. Each track invites listeners into a world shaped by adversity but defined by resilience, highlighting Tony’s skill in storytelling through music. This album promises not only to entertain but to inspire those who have faced their own shadows and found the strength to emerge into the light.

Through “Shadows,” Tony Levitas not only shares his personal story but also extends an invitation to listeners to explore their own resilience and the transformative power of music!

ABOUT

Atlanta’s own Tony Levitas, an accomplished singer, songwriter, and multi-instrumentalist, continues to make waves in the music scene with his latest album, “Shadows.” This new release marks his fifth solo project and reflects a profound journey of recovery and artistic exploration. The album, co-produced by Martin Kearns, Eytan Davidson, and Levitas himself, showcases his resilience and dedication to his craft.

As Tony Levitas continues to craft his path in the music industry, his work remains a beacon for authenticity and artistic integrity. With plans to continue writing, recording, and possibly collaborating with other artists and industries, the future looks bright for this seasoned musician. His journey is a compelling reminder of the power of music to heal, connect, and transcend even the toughest of times.

LINKS

Facebook: https://www.facebook.com/tony.levitas.5?mibextid=LQQJ4d

Spotify: https://open.spotify.com/artist/0ibW7dUejr6ExbOHsc5Gnu

Reverbnation: http://www.reverbnation.com/tonylevitas

Media Contact
Contact Person: Tony Levitas
Email: Send Email
Phone: 6786423107
City: Atlanta
State: Georgia
Country: United States
Website: https://www.facebook.com/tony.levitas.5?mibextid=LQQJ4d

Food Safety Testing Market to Progress Remarkably and Strike a 7.5% CAGR through 2031

“Skyquest Technology”

Food Safety Testing Market Size, Share, Growth Analysis, By Offering(Reagents & Consumables, Instruments, and Services), By  Contaminants(Pathogens (E.Coli, Salmonella, Campylobacter, Listeria), By Technology(Traditional, Rapid (Convenience-based, Polymerase Chain Reaction (PCR), Immunoassay)), By Food Type(Meat Poultry & Seafood, Dairy Products, Processed Food, Fruits & Vegetables), By Region – Industry Forecast 2024-2031

Food Safety Testing Market size was valued at USD 28.5 Billion in 2022 and is poised to grow from USD 30.69 Billion in 2023 to USD 55.53 Billion by 2031, growing at a CAGR of 7.5% in the forecast period (2024-2031).

The Global Food Safety Testing market has seen major evolutions in the past years with increased focus on systematic food product testing and the supply chain. Consumers demand food products that are safe and free from allergies, chemicals, and other potential risks. This ultimately forces the adoption of better food testing solutions that maintain customers’ trust and product recalls from the market.

Food testing processes have significantly witnessed a shift from the conventional approaches to modernized automated systems and AI to improve productivity and overcome the drawbacks of the old methods. These technologies offer better turnaround times and can achieve higher consistent outcomes with the help of automated repetitive processes and using (MLA) Machine Learning Algorithms. This enhances resource use and productivity. Moreover, automation of food testing streamlines real-time monitoring and studying of data by allowing the detection of early issues and immediate prompt advice. Therefore, food producers can improve their testing processes, examine the ability of their products, and considerably reduce risks or dangers. This then allows the guarantee of providing superior and safe food consumables to the end consumers.

Download a detailed overview:

https://www.skyquestt.com/sample-request/food-safety-testing-market

Implementation of Highly Advanced Technologies to Drive Food Product Testing

Compared to the former time-consuming food testing procedures, food producers today can quickly identify allergens, pollutants, and pathogens due to improved technologies like Polymerase Chain Reaction and Enzyme-Linked Immunosorbent Assay. They offer much faster and more precise results. The market has also adopted blockchain technology that helps transparency and traceability in supply chain processes. Using blockchain-powered technologies, food product testing data can be safely stored and shared throughout the supply chain, enabling stakeholders to track foods from farm to end user. Adopting these technologies in the supply chain significantly reduces the risk of theft, fraud, or contamination, while increasing accountability. Moreover, using sensor-based technologies, such as electronic noses and tongues allows a thorough assessment of quality. The technology can capably imitate human senses and efficiently detect the smallest distinction in scent, flavor, and texture. Nanotechnology is also used to enhance accuracy and detection and is currently actively used in food product testing. Besides these technologies, big data is also making a huge impact due to its extensive use. Food makers can make data-driven decisions by using large amounts of data created by testing techniques to know important details about consumer choices, quality of products, and market trends.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/food-safety-testing-market

The Eurofins Microbiology Laboratories, in June 2024, announced the launch of a novel test technique to be used by beverage makers. The technique is mainly developed for acetic acid bacteria enumeration. The company offers this test to meet the demands of the beverages industry as a component of multiple beverage packages.
In September 2022, Intertek announced the launching of the novel Vegan Foods Certification. The demand for vegan foods has increased significantly in the last few years. Mainly, youths and adults are more inclined towards personal well-being and health, transparency of their consumable products, and environmental effects. This leads to people exploring new types of plant-based or vegan lifestyles.
In June 2023, Bureau Veritas announced the launch of its 4th United States Food Laboratory, Chesterfield, in Missouri. It offers speedy and traditional microbiology testing for agriculture and food products. The new laboratory’s activities aid the food market comprising examination of agricultural products, testing, grading, and GFSI (Global Food Safety Initiative) certification and training facilities.
In April 2024, Mérieux NutriSciences and bioMérieux revealed the launch of a novel data-driven Trusted 3rd Party initiative made with the team of food industry partners to nurture safe industry partnerships and also better predict and avoid food safety dangers. Despite efforts and initiatives for food safety, the market still witnesses a few quality and safety issues. The changing scenario and improving food safety solutions demand improved services based on mainly auditing, testing, and certification.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/food-safety-testing-market

With the evolving food industry, food safety and testing approaches are also advancing. The future of food safety testing will hence comprise increased productivity, welcoming of innovations, and maintaining the company’s commitment. The food makers can hence satisfy ever-changing consumer demand on the global scale and negotiate intricacies of modern foods by spending superior technologies and staying updated with the existing trends.

Related Reports:

Quantum Computing Market

Visit Our Website: https://www.skyquestt.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Food Safety Testing Market to Progress Remarkably and Strike a 7.5% CAGR through 2031

Cough in Idiopathic Pulmonary Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cough in Idiopathic Pulmonary Fibrosis pipeline constitutes 5+ key companies continuously working towards developing 5+ Cough in Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Cough in Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cough in Idiopathic Pulmonary Fibrosis Market.

The Cough in Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Cough in Idiopathic Pulmonary Fibrosis Pipeline Report:

Companies across the globe are diligently working toward developing novel Cough in Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
Cough in Idiopathic Pulmonary Fibrosis companies working in the treatment market are NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others, are developing therapies for the Cough in Idiopathic Pulmonary Fibrosis treatment

Emerging Cough in Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others are expected to have a significant impact on the Cough in Idiopathic Pulmonary Fibrosis market in the coming years.
In March 2024, US-based Seyltx has finalized an agreement to acquire Algernon Pharmaceuticals’ chronic cough therapy, ifenprodil (NP-120). Algernon received $2 million and a 20% equity stake in Seyltx as part of the deal. Ifenprodil, an N-methyl-D-aspartate (NMDA) receptor antagonist, specifically targets the NMDA type subunit 2B (GluN2B). Data from the Phase II trial conducted in Australia and New Zealand demonstrated a reduction in cough count among patients with idiopathic pulmonary fibrosis (IPF) and chronic cough compared to baseline.
In December 2023, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, is developing Haduvio™ (oral nalbuphine ER) for patients with chronic cough associated with idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. The company announced the start of its Phase 2b CORAL clinical trial, which will assess three doses of Haduvio against a placebo in around 160 IPF patients with chronic cough. This Phase 2b trial follows the successful Phase 2a CANAL trial, which showed a statistically significant 75.1% reduction in daytime cough frequency, representing a 52.5% difference from placebo (p<0.0001).

Cough in Idiopathic Pulmonary Fibrosis Overview

Cough in Idiopathic Pulmonary Fibrosis (IPF) is a common symptom characterized by a persistent and often dry cough that worsens over time. It is a hallmark of the disease and can significantly impact a patient’s quality of life. The cough in IPF is usually non-productive, meaning it does not produce mucus or phlegm.

Get a Free Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Cough in Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

Orvepitant Maleate: NeRRe Therapeutics
Haduvio (nalbuphine ER): Trevi Therapeutics
ME-015 (Suplatast Tosilate): Melius Pharma AB
BI 1839100: Boehringer Ingelheim

Cough in Idiopathic Pulmonary Fibrosis Route of Administration

Cough in Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Cough in Idiopathic Pulmonary Fibrosis Molecule Type

Cough in Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

Cough in Idiopathic Pulmonary Fibrosis Assessment by Product Type
Cough in Idiopathic Pulmonary Fibrosis By Stage and Product Type
Cough in Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
Cough in Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
Cough in Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
Cough in Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Cough in Idiopathic Pulmonary Fibrosis Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Cough in Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Cough in Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Cough in Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Cough in Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Cough in Idiopathic Pulmonary Fibrosis are – Algernon Pharmaceuticals, Seyltx Inc., Melius Pharma AB, NeRRe Therapeutics, Trevi Therapeutics, Cellular Sciences, Emphycorp, and others.

Cough in Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Cough in Idiopathic Pulmonary Fibrosis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Cough in Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cough in Idiopathic Pulmonary Fibrosis Treatment.
Cough in Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cough in Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cough in Idiopathic Pulmonary Fibrosis market.

Download Sample PDF Report to know more about Cough in Idiopathic Pulmonary Fibrosis drugs and therapies

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

High Unmet Need, Growing Patient Population, Advancements in Research, Regulatory Support, Increased Investment, are some of the important factors that are fueling the Cough in Idiopathic Pulmonary Fibrosis Market.

Cough in Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

However, Complex Disease Pathophysiology, Clinical Trial Challenges, Competitive Landscape, and other factors are creating obstacles in the Cough in Idiopathic Pulmonary Fibrosis Market growth.

Scope of Cough in Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

Coverage: Global
Key Cough in Idiopathic Pulmonary Fibrosis Companies: NeRRe Therapeutics, Trevi Therapeutics, Melius Pharma AB, Boehringer Ingelheim, and others
Key Cough in Idiopathic Pulmonary Fibrosis Therapies: Orvepitant Maleate, Haduvio (nalbuphine ER), ME-015 (Suplatast Tosilate) BI 1839100, and others
Cough in Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Cough in Idiopathic Pulmonary Fibrosis current marketed and Cough in Idiopathic Pulmonary Fibrosis emerging therapies
Cough in Idiopathic Pulmonary Fibrosis Market Dynamics: Cough in Idiopathic Pulmonary Fibrosis market drivers and Cough in Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Cough in Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Cough in Idiopathic Pulmonary Fibrosis Report Introduction

2. Cough in Idiopathic Pulmonary Fibrosis Executive Summary

3. Cough in Idiopathic Pulmonary Fibrosis Overview

4. Cough in Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Cough in Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Cough in Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Cough in Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Cough in Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Cough in Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Cough in Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Cough in Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cough in Idiopathic Pulmonary Fibrosis Key Companies

14. Cough in Idiopathic Pulmonary Fibrosis Key Products

15. Cough in Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Cough in Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Cough in Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Cough in Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cough in Idiopathic Pulmonary Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics

Industry 4.0 Market to Progress Remarkably and Strike a 16.2% CAGR through 2031

“Skyquest Technology”

Industry 4.0 Market Size, Share, Growth Analysis, By Technology(Robots (Traditional Industrial Robots {Articulated robots, Cartesian Robots, Selective Compliance Assembly Robot Arm (SCARA), Cylindrical Robots), By Industry(Manufacturing, Automotive, Energy, Medical), By Region – Industry Forecast 2024-2031

Industry 4.0 Market size was valued at USD 133.05 billion in 2022 and is poised to grow from USD 154.6 billion in 2023 to USD 513.89 billion by 2031, growing at a CAGR of 16.2% during the forecast period (2024-2031).

Industry 4.0 market is highly driven by the mounting use of digital technologies like Artificial Intelligence, Big Data Analytics, and the Internet of Things in the manufacturing industry. These technologies are deeply intertwined in the manufacturing processes. This integrated and unified approach to production leads to better products, assets, and factories. Hence, manufacturing businesses today are increasingly adopting IoT-linked machines.

Download a detailed overview:

https://www.skyquestt.com/sample-request/industry-4-0-market

Industry 4.0 when implemented, unravels unparalleled value in different networks and functions. This comprises everything starting from information and processing capabilities to human-machine communication, intelligence and analytics, and novel production techniques. With the advancements in technology, there is growing pressure to enter Industry 4.0 for better continuity. Nonetheless, the companies need to emphasize on main objectives, deal with the existing complexities, and improve scalable solutions that may be scaled out through the company network. Furthermore, in place of planning 10 years or more prior, 3-5 years of roadmap is considered more practical. In short, industry 4.0 is the transformation of production, manufacturing, and most other associated sectors. Industry 4.0 presents a fresh phase in business and industrial value chain control.

Expanding Use of Technologies like AI, IoT, Robotics, and more to Drive Adoption of Industry 4.0

The Internet of Things is specially designed to link the virtual and the real world, and several businesses have already understood its importance. IoT is today an indispensable tool in tracking shipments, automobiles, wearable devices, and more. In the world of Industry 4.0, companies can use IoT to gather data and measure consumer choices and product usage more efficiently for better customer satisfaction. The Internet of Things holds applications in multiple sectors. AI is another technology, in which manufacturing companies can enhance their production volume, automate repetitive tasks, make better use of time, resources, money, and simply operations. Yet another technology, Blockchain, is a decentralized and secure way of collecting and sharing information for businesses. Though blockchain is prominent in the cryptocurrency domain, it has applications in various sectors like securing confidential information in the healthcare industry, in the supply chain for improved visibility, and more. The market is also seeing the implementation of robotics since the technology proved to be advantageous for businesses. Robotics, a main technology in Industry 4.0 holds the potential to transform business in different verticals and deliver the best value mainly in production, healthcare, and manufacturing.

Request Free Customization of this report:

https://www.skyquestt.com/speak-with-analyst/industry-4-0-market

In January 2023, Siemens Digital Industries Software announced the launch of Explore Live at The Smart Factory. It is an experience center organized by Deloitte that combines business strategy and cutting-edge technology with an ecosystem of top global companies to illustrate Industry 4.0. The Smart Factory boasts an entirely functional production line along with interactive labs specially designed to nurture the exploration and development of the potential of smart manufacturing’s invention.
Cisco launched Cisco LIVE 2024 in June 2024 with fresh AI-enabled investments and advancements, sending a strong message that Artificial Intelligence is more than just the newest trend in technology. It is a powerful, smart digital resilience source that can enable growth, scale, and an inclusive future for all while connecting and safeguarding entire enterprises.
In April 2024, Schneider Electric, a leading company in automation and energy management, presented the recent innovations in its range of products. This comprises Artificial Intelligence, Digital Twin technology, and industrial software. These solutions will be revealed via the sustainable and digital life science campus lens. This will highlight Schneider’s exhaustive domain expertise across the whole industrial value chain.
In November 2023, Emerson, a Global engineering and software leader participated as a gold sponsor in the MAINTCON 2022. This exhibition underlines the importance of Industry 4.0 and developing advancements in reliability, maintenance, and asset management. The event theme mainly emphasizes the importance of Industry 4.0 and the escorting technological developments that will drive the market positively.

View report summary and Table of Contents (TOC):

https://www.skyquestt.com/report/industry-4-0-market

Today, Industry 4.0 is regarded as more than a technology with several benefits to businesses. They can efficiently reduce downtime, improve their resource allocation, enhance productivity, and more. This increased efficiency then allows for sustainability creativities, where smart automation and analytics help simplify and optimize the use of energy, design innovative products, and reduce waste.

Related Reports:

Edge Computing Market

Visit Our Website: https://www.skyquestt.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Industry 4.0 Market to Progress Remarkably and Strike a 16.2% CAGR through 2031

Top Real Estate Agent in Wesley Chapel, FL, Closes 205th Sale, Celebrating Continued Success

Michelle Moreno, a top real estate agent in Wesley Chapel, FL, has recently achieved a significant milestone in her career with the closing of her 205th sale. This accomplishment is a testament to Michelle’s unwavering dedication to client satisfaction and her unmatched expertise in the Wesley Chapel real estate market. Michelle’s success can be attributed to her commitment to excellence and her clients’ trust in her services.

“Reaching 205 sales is a testament to our team’s commitment to excellence and our clients’ trust in our services,” says Michelle Moreno, leading Realtor in Wesley Chapel, FL. “We strive to exceed expectations with every transaction, providing tailored solutions that meet the unique needs of each client.”

As a professional Realtor agent in Wesley Chapel, FL, Michelle credits her success to her deep understanding of local market trends and her dedication to providing exceptional customer service. “Our business growth mirrors the population surge in Greater Tampa Bay,” notes Michelle. “This expansion underscores the confidence our clients have in our ability to deliver results” she adds. Michelle’s reputation for excellence extends beyond local clients, as she recently assisted a client from Atlanta who was drawn to her stellar reputation and military affiliation.

Michelle’s commitment to serving clients nationwide is evident in her invitation for clients to experience her top-tier service firsthand. She is honored to assist clients from various locations and is dedicated to providing them with the same level of excellence that has earned her a reputation as one of the top Wesley Chapel, FL Realtors. Michelle’s success is a result of her unwavering dedication to her clients and her ability to adapt to the evolving real estate landscape. “We’re honored to serve clients nationwide and invite them to experience our top-tier service firsthand,” she encourages.

Michelle’s expertise, commitment to excellence, and dedication to client satisfaction have positioned her as a leading realtor. For those interested in learning more about Michelle Moreno and her real estate services, visit her website at keytosold.kw.com.

Media Contact
Company Name: Key to Sold Team | Keller Williams Tampa Properties | Real Estate Agent in Wesley Chapel FL
Contact Person: Michelle Moreno
Email: Send Email
Phone: +1 813-523-6613
City: Wesley Chapel
State: Florida
Country: United States
Website: https://keytosold.kw.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Wesley Chapel, FL, Closes 205th Sale, Celebrating Continued Success